Clincosm LogoSign in Get a demo

Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia

Sponsor
UL-PIRE Africa Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05888649
Collaborator
West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP) (Other)
1,500
Enrollment
1
Location
23
Anticipated Duration (Months)
65.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This community-based mixed methods study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations, including acceptance for Ebola vaccines.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Community Clusters

Detailed Description

This community-based study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations and acceptance for the administration of Ebola vaccination. The investigators will conduct an anthropologically driven mixed methods study design that comprises both qualitative and quantitative research methods for the successful implementation of this community-based study. The investigators will conduct structured interviews with community members and local responders to broadly assess and understand the perspectives regarding appropriate strategies previously employed to effectively support community preparedness during outbreak response and also to broadly access and understand appropriate strategies previously employed to effectively support community acceptance for Ebola vaccines, respectively. Learning from the experiences of local voices produces globally emergent systems that are trusted, reliable and sustainable.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
Community Preparedness for Outbreak Response and Readiness for ZEBOV Vaccination in Liberia
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Apr 30, 2025
Anticipated Study Completion Date :
Apr 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Cluster 1

Communities highly affected and impacted by EVD

Behavioral: Community Clusters
Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Other Names:
  • Community Cohorts

    		•
    Cluster 2

    Communities not highly affected and impacted by EVD

    Behavioral: Community Clusters
    Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
    Other Names:
  • Community Cohorts

    		•
    Cluster 3

    Communities receptive to EVD vaccination

    Behavioral: Community Clusters
    Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
    Other Names:
  • Community Cohorts

    		•
    Cluster 4

    Communities resistance to EVD vaccination

    Behavioral: Community Clusters
    Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
    Other Names:
  • Community Cohorts

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Measure #1 [2 Years]

      Assess Community Preparedness with the Resiliency Scale

    2. Measure #2 [2 Years]

      Assess Community Acceptance of EVD Vaccine with the Resiliency Scale

    Secondary Outcome Measures

    1. Measure #3 [2 Years]

      Assess Roles of Community Leaders with the Resiliency Scale

    2. Measure #4 [2 Years]

      Assess Roles of Formal and Informal Community Structures with the Resiliency Scale

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Adults

    • Community Leaders

    • Community Members

    • Reside in 1 of 3 highly prevalent counties

    • Participated actively in EVD outbreaks related activities

    • Documented roles recognized by the Incident Management System

    Exclusion Criteria:

    • Not Adults

    • Does not reside in any of the 3 highly prevalent counties

    • Did not actively participate in the EVD outbreak response related activities

    • Roles not documented by the Incident Management System

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Montserrado, Margibi and Lofa Counties Monrovia Montserrado County Liberia 1000

    Sponsors and Collaborators

    • UL-PIRE Africa Center
    • West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP)

    Investigators

    • Principal Investigator: Stephen B Kennedy, MD, MPH, UL-PIRE Africa Center, University of Liberia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    UL-PIRE Africa Center
    ClinicalTrials.gov Identifier:
    NCT05888649
    Other Study ID Numbers:
    • MISP 101054
    First Posted:
    Jun 5, 2023
    Last Update Posted:
    Jun 5, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by UL-PIRE Africa Center
    Community Preparedness
    Outbreak Response
    Ebola Virus Disease (EVD)
    Ebola Vaccine
    Ebola Vaccine Acceptance
    Community Leaders
    Liberia
    Additional relevant MeSH terms:
    Virus Diseases
    Hemorrhagic Fever, Ebola

    Study Results

    No Results Posted as of Jun 5, 2023